Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus chemotherapy with 18F-FDG PET-CT selection followed by concurrent chemoradiotherapy or surgery in resectable esophageal squamous cell carcinoma
ChiCTR2600129557Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Median Event-Free Survival (EFS). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600129557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129557.